A Novo spokesperson said the Danish drugmaker was not ruling out further legal action after announcing new lawsuits against ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

PNC Financial Services Group Inc. lifted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 123.8% ...

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

Kodiak Robotics has appointed former Cruise CTO Mohamed Elshenawy to its board as it moves toward a public listing in late ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...

Hims stock has been volatile but has doubled so far this year. Supermicro shares are retreating after a long run.

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

The Microdose GLP-1Rx Program will offer low-dose GLP-1 prescriptions combined with behavioral coaching, clinical monitoring and medication management.

Hims & Hers is a top telehealth stock with strong revenue growth, innovative offerings, and long-term potential. Click here ...